{
  "folder": "IC-201",
  "content": "{{knowledge objective\n|Identifiant=OIC-201-08-B\n|Item_parent=Organ transplants: epidemiological and immunological aspects; principles of treatment and monitoring; complications and prognosis; ethical and legal aspects. Organ procurement and legislation\n|Item_parent_short=Organ transplants: epidemiological and immunological aspects; principles of treatment and monitoring; complications and prognosis; ethical and legal aspects. Organ procurement and legislation\n|Rank=B\n|Title=Know the main classes of immunosuppressive drugs used in organ transplantation.\n|Description=None\n|Rubric=Management\n|Contributors=Dany Anglicheau\n|Order=8}}\n\nImmunosuppression is intended to :\n\n*Prevent acute rejection in the initial phase (induction treatment);\n*prevent rejection after the initial phase (maintenance treatment);\n*treat acute rejection (curative treatment).\n\n\nInduction treatment :\n\n*It allows strong immunosuppression to be introduced during the first few days of transplantation, when the risk of rejection is highest.\n*The molecules used are polyclonal antibodies that deplete T lymphocytes or a non-depleting monoclonal antibody.\n\n\nMaintenance treatment :\n\n*The aim is to prevent the occurrence of an acute rejection episode in the long term, with the least possible iatrogenicity.\n*Maintenance treatment usually involves a combination of 2 or 3 immunosuppressive agents from different families (Table 2).\n\nImmunosuppressive treatment increases the risk of infectious and tumour complications, warranting [[Follow-up of immunosuppressed patients SD-291|suu suivi sp\u00e9cialis\u00e9]].\n\n\nTable 2: Main classes of immunosuppressants targeting T lymphocytes\n{| class=\"wikitable\"\n|Mechanisms of action\n|Therapeutic class\n|Molecules\n|-\n|Depletion of circulating T lymphocytes\n|Anti-lymphocyte antibodies\n|Anti-lymphocyte polyclonal antibodies\n|-\n| rowspan=\"2\" |Inhibitors of lymphocyte activation (signal 1 and signal 2)\n|Inhibitors of T-receptor engagement signal 1\n|Calcineurin inhibitors (ciclosporin and tacrolimus)\n|-\n|Signal 2 inhibitors (inhibition of costimulation)\n|Belatacept\n|-\n|Inhibitors of lymphocyte proliferation (signal 3)\n|by inhibiting the action of IL-2 on its receptor\n|Antibodies directed against the CD25 chain of the IL-2 receptor (basiliximab)\n|-\n|inhibition of cell proliferation\n|mTOR inhibitors (sirolimus, everolimus)\n|-\n|Purine base inhibition\n|Azathioprine\n\nMycophenolic acid\n|-\n|Anti-inflammatory and immunosuppressant\n|Corticosteroids\n|Prescribing systemic or local corticosteroids SD-251|Corticosteroids\n|}",
  "question": {
    "question": "Which class of immunosuppressive drugs is primarily used for the induction treatment phase to prevent acute rejection immediately following organ transplantation?",
    "option_a": "Calcineurin inhibitors",
    "option_b": "Anti-lymphocyte polyclonal antibodies",
    "option_c": "mTOR inhibitors",
    "option_d": "Anti-inflammatory and immunosuppressant corticosteroids",
    "correct_option": "B"
  }
}